SAREPTA THERAPEUTICS, INC. Payments to Acquire Restricted Investments
SAREPTA THERAPEUTICS, INC. (SRPT) reported Payments to Acquire Restricted Investments of $353.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2020-02-26.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireRestrictedInvestments · last filed 2020-02-26
- SAREPTA THERAPEUTICS, INC. payments to acquire restricted investments for the quarter ending 2018-12-31 was $0.00.
- SAREPTA THERAPEUTICS, INC. payments to acquire restricted investments for the quarter ending 2018-09-30 was $0.00.
- SAREPTA THERAPEUTICS, INC. payments to acquire restricted investments for the quarter ending 2015-12-31 was $0.00.
- SAREPTA THERAPEUTICS, INC. payments to acquire restricted investments for the quarter ending 2014-09-30 was $0.00.
- SAREPTA THERAPEUTICS, INC. payments to acquire restricted investments for fiscal 2018 was $353.00K.
- SAREPTA THERAPEUTICS, INC. payments to acquire restricted investments for fiscal 2015 was $10.70M.
- SAREPTA THERAPEUTICS, INC. payments to acquire restricted investments for fiscal 2013 was $7.90M.
| Period end | Payments to Acquire Restricted Investments 1 month | Payments to Acquire Restricted Investments 3 month | Payments to Acquire Restricted Investments 6 month | Payments to Acquire Restricted Investments 9 month | Payments to Acquire Restricted Investments 12 month | Payments to Acquire Restricted Investments 395 month | Payments to Acquire Restricted Investments 398 month | Payments to Acquire Restricted Investments 401 month | Payments to Acquire Restricted Investments 404 month |
|---|---|---|---|---|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $0.00 derived: sum of 2 quarters · filed 2020-02-26 | $353.00K 10-K · filed 2020-02-26 | ||||||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $353.00K 10-Q · filed 2019-11-07 | |||||||
| 2018-06-30 | $353.00K 10-Q · filed 2019-08-07 | ||||||||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $10.70M 10-K · filed 2018-03-01 | |||||||
| 2015-09-30 | $10.70M 10-Q · filed 2015-11-05 | $10.70M 10-Q · filed 2016-11-07 | |||||||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $0.00 10-Q · filed 2014-11-06 | |||||||
| 2014-06-30 | $0.00 10-Q · filed 2014-08-07 | ||||||||
| 2014-03-31 | $7.90M 10-Q · filed 2014-05-08 | ||||||||
| 2013-12-31 | $90.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $90.00K derived: sum of 2 quarters · filed 2016-02-25 | $647.00K derived: sum of 3 quarters · filed 2016-02-25 | $7.90M 10-K · filed 2016-02-25 | $7.90M 10-K · filed 2014-03-03 | ||||
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $557.00K derived: sum of 2 quarters · filed 2014-11-06 | $7.81M 10-Q · filed 2014-11-06 | $7.81M 10-Q · filed 2013-11-12 | |||||
| 2013-06-30 | $557.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $7.81M 10-Q · filed 2014-08-07 | $7.81M 10-Q · filed 2013-08-08 | ||||||
| 2013-03-31 | $7.25M 10-Q · filed 2014-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |